Genmab Announces European Regulatory Submission for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma

Company Announcement

  • Application to broaden label for daratumumab for relapsed multiple myeloma submitted to EMA by Janssen
  • Submission based on data from two Phase III studies, CASTOR and POLLUX
  • Genmab to receive USD 10 million in milestone payments from Janssen

Copenhagen, Denmark; August 23, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Janssen Pharmaceutica NV (Janssen) has submitted a variation to the Marketing Authorization to the European Medicines Agency (EMA) seeking to broaden the existing marketing authorization for daratumumab (DARZALEX®) to include treatment of adult patients with multiple myeloma who have received at least one prior therapy. The submission of the application triggers milestone payments totaling USD 10 million to Genmab from Janssen. The milestone payments were included in Genmab’s financial guidance for 2016 that was published on August 9, 2016. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

“Daratumumab represents a new hope for people suffering from multiple myeloma, a disease which is presently incurable. We look forward to working together with Janssen and the EMA to making daratumumab available to a far wider group of patients,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The submission includes data from two Phase III studies: the CASTOR study of daratumumab in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma, and the POLLUX study of daratumumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.  The submission also included data from the Phase I study of daratumumab in combination with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.

Janssen submitted a supplemental Biologics License Application for daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for treatment of patients with multiple myeloma who received at least one prior therapy to the U.S. Food and Drug Administration in August 2016.

About multiple myeloma Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells. 1 Multiple myeloma is the third most common blood cancer in the U.S., after leukemia and lymphoma. 2 Approximately 30,330 new patients are expected to be diagnosed with multiple myeloma and approximately 12,650 people are expected to die from the disease in the U.S. in 2016. 3 Globally, it was estimated that 124,225 people would be diagnosed and 87,084 would die from the disease in 2015. 4   While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, kidney problems or infections. 5 Patients who relapse after treatment with standard therapies, including proteasome inhibitors or immunomodulatory agents, have poor prognoses and few treatment options. 6

About DARZALEX ® (daratumumab) DARZALEX ® (daratumumab) injection for intravenous infusion is indicated in the United States for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent. 7 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.  For more information, visit www.DARZALEX.com .  

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. It is believed to induce rapid tumor cell death through programmed cell death, or apoptosis, 7,8 and multiple immune-mediated mechanisms, including complement-dependent cytotoxicity, 7,8 antibody-dependent cellular phagocytosis 9,10 and antibody-dependent cellular cytotoxicity. 7,8   In addition, daratumumab therapy results in a reduction of immune-suppressive myeloid derived suppressor cells (MDSCs) and subsets of regulatory T cells (Tregs) and B cells (Bregs), all of which express CD38. These reductions in MDSCs, Tregs and Bregs were accompanied by increases in CD4+ and CD8+ T cell numbers in both the peripheral blood and bone marrow. 7,11

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. Five Phase III clinical studies with daratumumab in relapsed and frontline settings are currently ongoing, and additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant diseases on which CD38 is expressed, such as smoldering myeloma, non-Hodgkin’s lymphoma and a solid tumor.  

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .   

Contact:           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law. Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo ® ; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Biotech, Inc.

1 American Cancer Society. "Multiple Myeloma Overview." Available at http://www.cancer.org/cancer/multiplemyeloma/...le-myeloma . Accessed June 2016.

2   National Cancer Institute. "A Snapshot of Myeloma." Available at www.cancer.gov/research/progress/snapshots/myeloma. Accessed June 2016.

3   American Cancer Society. "What are the key statistics about multiple myeloma?" http://www.cancer.org/cancer/multiplemyeloma/...statistics. Accessed June 2016.

4   GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide: Number of New Cancers in 2015. Available at: http://globocan.iarc.fr/old/burden.asp?select...%A0Execute. Accessed June 2016.

5   American Cancer Society. "How is Multiple Myeloma Diagnosed?" http://www.cancer.org/cancer/multiplemyeloma/...-diagnosis. Accessed June 2016.

6 Kumar, SK et al. Risk of progression and survival in multiple myeloma relapsing after last therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012; 26:149-57.

7 DARZALEX US Prescribing Information, November 2015.  

8 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.

9 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.

10 Khagi, Y and  Mark, TM. Potential role of daratumumab in the treatment of multiple myeloma. Onco Targets Ther. 2014; 7: 1095–1100.

11 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.

Company Announcement no. 38 CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 46

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 97

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 60

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 57

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

Natural Food Color Industry Expected to Thrive by 2035

Updated Category News Views 167

Revitalizing the Natural Food Colors Market The natural food colors market is poised for remarkable growth, projected to expand from USD 2.01 billion to USD 4.03 billion by 2035. Market analysts suggest this surge will take place at a Compound Annual Growth Rate (CAGR) of 7.8%. This transformation is largely attributed to a shift in consumer preferences, regulatory...

Continue Reading
Fang Holdings Strengthens Leadership with Board Changes

Updated Category News Views 98

Fang Holdings Limited Announces Leadership Changes Fang Holdings Limited (OTC: SFUNY) has officially confirmed changes within its board of directors, marking an important phase for the company. As a prominent real estate Internet portal, Fang is committed to providing exceptional services to its users, and these changes in leadership are expected to support its strategic...

Continue Reading
NovaBridge's Visara Appoints Leaders to Propel Eye Treatment

Updated Category News Views 235

NovaBridge's Strategic Moves in Ophthalmology In a significant step forward for innovative treatment in ophthalmology, NovaBridge Biosciences (NASDAQ: NBP) has announced new appointments at its subsidiary, Visara, Inc. Cadmus C. Rich, MD, MBA, has been named Chief Medical Officer, while Carlos Quezada-Ruiz, MD, FASRS, takes the role of Chair of the Scientific Advisory...

Continue Reading
Celebrating Excellence: The Grossman Group's 25-Year Journey

Updated Category News Views 274

The Grossman Group Celebrates 25 Years of Communication Excellence In a prestigious recognition, The Grossman Group has earned the title of Best Small Agency at the Public Relations Society of America's 2025 Silver Anvil Awards. This honor comes during a significant milestone—the company's 25th anniversary—marked by years of dedication to enhancing internal...

Continue Reading
GiGi's Playhouse Celebrates the Opening of Its 61st Center in the Northwest

Updated Category News Views 360

GiGi's Playhouse unveiled its 61st Achievement Center back in the fall of a recent year, pushing forward its mission to uplift individuals impacted by Down syndrome. The grand opening of this center wasn’t just another launch—it was a culmination of seven years filled with passion, community spirit, and unwavering dedication from parents who aimed to create a haven...

Continue Reading